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Abstract 
Westerlind, U. 2005. Chemical Synthesis of Carbohydrates and Glycopeptides for 
Biological Application. Doctor’s dissertation. 
ISSN 1652-6880, ISBN 91-576-6991-0 
 
This thesis describes chemical synthesis of carbohydrates and glycopeptides useful in 
studies of biologically interesting systems. The following topics are addressed: [Papers I-IV 
and supporting information]: 
  [I] The non-reducing end di- and trisaccharide structures of an erythrocyte glycolipid 
responsible for the rare NOR polyagglutination were chemically synthesized. The syntheses 
were based on a -D-Galp-(14)--D-GalpNAc-(1) structural element found only 
recently in Nature, and derivatives thereof have not been synthesized before. Both the 
synthesized oligosaccharides specifically inhibited human anti-NOR antibodies, with the 
trisaccharide being 300 times more active than the disaccharide. 
  [II] Derivatives of lactose with the galactose ring substituents replaced by 2´, 3´, 4´ and 6´ 
deoxy and 3´ acylamino functions were prepared. The lactosyl derivatives were tested as 
acceptors for the Neisseria menigitidis N-acetylglucosaminyltransferase catalyzed -(13) 
glycosylation reaction, using UDP-GlcNAc as donor. The 6´-deoxy compound showed 
nearly a threefold increase in activity compared with the reference substance phenyl -
lactoside, whereas the 2´ and 4´-deoxy derivatives were less active. The 3´-deoxy and 3´-
acylamino derivatives will be used in studies of the inhibitory capacity.  
  [III] In order to develop the non-viral Bioplex vector system for non-viral gene delivery 
to hepatocytes, biotinylated ligands were synthesised to study the structure-function 
relationship of specific binding and uptake to the asialoglycoprotein receptor ASGPr. 
Cluster glycosides containing two, three and six -D-GalpNAc residues were synthesized 
and tested for binding and uptake to liver cells. The derivative displaying six GalNAc units 
showed the highest uptake efficacy. However, the number of GalNAc units above three 
seems only to have a minor contribution to the overall affinity, while using longer spacer 
between the GalNAc ligands markedly influenced the uptake efficacy. 
  [IV] An analgetically active glycopeptide from the cone snail Conus geographus, 
contulakin G, has recently been analyzed and synthesized. Contulakin-G has been found to 
be a neurotensin agonist and have entered pre-clinical trials for short-term management of 
post-operative pain. The glycan part of contulakin-G has been found to be important for the 
biological in vivo activity. In order to further investigate the importance of the glycan part, 
three analogues of contulakin-G have been synthesized, were the / conformation of the 
anomeric centers as well as the glycosidic bond pattern of the disaccharide have been 
altered.  
  In addition to the contulakin G analogues, a heavily posttranslational modified 
glycopeptide from Conus textile, tx5a, has been synthesized.  
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Abbreviations 
5-HT 5-Hydroxy-tryptamine  (Serotonin) 
Å Ångström 
Ac Acetyl 
All Allyl 
ASGPr Asialoglycoprotein  receptor 
Bn Benzyl 
Boc tert-Butoxycarbonyl 
Bz Benzoyl 
CRD  Carbohydrate recognition domain 
DBU Diazabicycloundecan 
DCC Dicyclohexylcarbdiimide 
DCM Dichloromethane 
DIPEA  N,N-Diisopropyl-N-ethylamine 
DMAP 4-(N,N-Dimethylamino)pyridine 
DMF Dimethylformamide 
DMSO Dimethylsulphoxide 
DMTST Dimethyl(thio-methyl)sulfonium 
trifluoromethanesulfonate 
DNA Deoxyribonucleic  acid 
E. Coli  Escherichia coli 
equiv. Equivalent(s) 
Et Ethyl 
FACS Fluorescence-activated  cell  sorting 
Fmoc Fluoren-9-ylmethoxycarbonyl 
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GalNAc  N-Acetylgalactosamine 
Glc Glucose 
GlcNAc  N-Acetylglucosamine 
GLUT Glucose  transporter 
h hour(s) 
HBTU [N-[(1H-benzotriazol-1-
yl)(dimethylamino)methylene]-N-
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+ PF6
- 
HOBt 1-N-Hydroxybenzotriazole 
HPLC  High performance liquid chromatography 
i-Pr  iso-Propyl 
MALDI  Matrix assisted laser desorption ionization 
Me Methyl 
MS Molecular  sieves 
Mtt 4-Methyltrityl 
nAChR Nicotinic  acetylcholine  receptor 
NBS  N-Bromosuccinimide 
NMDA  N-methyl-D-aspartate  10
NMR Nuclear  magnetic  resonance 
NOE Nuclear  overhauser  effect 
NOR  named from the city of first case, NORton  
NTR Neurotensin  receptor 
O.N. overnight 
Ph Phenyl 
Phen Phenacyl 
Phth Phthalimido 
PNA  peptide nucleic acid 
p-Tol  para-Tolyl 
PyBOP  [Benzotriazol-1-yl-
oxytris(pyrrolidino)phosphonium]
+PF6
- 
RP Reversed  phase 
rt Room  temperature  ( 23° C) 
SPE  Solid phase extraction 
t-Bu  tert-Butyl 
TCEP tris-(2-carboxyethyl)-phosphine 
hydrochloride 
Tf Trifluoromethanesulfonyl 
TFA Trifluoroacetic  acid 
THF Tetrahydrofuran 
TIPS Triisopropylsilane   
TMS Trimethylsilyl 
TOF  Time Of Flight 
TSDU  [Succinimidyl-1,3-dimethyl-1,3-
trimethyleneuronium]
+BF4
- 
UDP Uridine  diphosphate 
Wilkinsons catalyst  (PPh3)3RhCl 
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1. Introduction 
1.1 Historical background 
Carbohydrates represent a unique family of poly-functional compounds possessing 
a rich chemistry and extraordinary complex biology. As most compound classes, 
carbohydrates can be chemically manipulated in a multitude of ways. The 
chemistry of carbohydrates has during its more than hundred years long history 
developed into a discipline of its own. Emil Fischer, later awarded the Nobel Prize 
in 1902, laid the basis of understanding of the organic chemistry of the 
carbohydrates in Germany at the end of 19
th century. Fisher established systematic 
methods for the nomenclature and configurational assignment of carbohydrates.
[1] 
Another great contribution to the whole field of organic chemistry was that Fischer 
continued the fundamental studies of the phenomenon named chirality. Initially 
discovered by the French scientists Hauy and Biot
[2], chirality became a matter of 
general interest due to Pasteur´s seminal studies during mid 19
th century, that 
postulated that the optical activity of molecules is a consequence of three-
dimensional isomerism
[3]. Pasteur mainly investigated natural and synthetic 
derivatives of tartaric acid, while Fischer extended the investigations into the most 
commonly abundant group of naturally occurring chiral compounds, namely 
carbohydrates. Fischer showed that enantiomers of a given molecule rotate the 
plane of polarized light with the same magnitude but in opposite direction. Further, 
he put forward that (d)- and (l)-symbols should be independent of the direction of 
rotation and that they should be used only to denote the spatial orientation of the 
substituents. Fischer also created the Fischer projection, a two-dimensional 
formula used to relate the configurations of chiral molecules and according to this 
system an assumption of the absolute configuration of glucose, galactose, 
mannose, fructose, arabinose and xylose was made.
[4, 5] This assumption was 75 
years later proven to be correct by X-ray structural analysis.
[6] In the early days of 
carbohydrate chemistry, melting point and optical rotation were essential in the 
determination of chemical structure and equivalence. Pure crystalline compounds 
were necessary for identification and the purification of sugar syrups by 
distillation, the most important purification technique before chromatography, was 
not a good alternative due to extensive decomposition. This limited the scope of 
carbohydrate research and it was not until the 1960s, when chromatographic 
methods and NMR spectroscopy were developed, that isolation of carbohydrate 
derivatives and their structural analysis became more feasible. During modern 
times, many scientists have contributed to the field of synthetic carbohydrate 
chemistry, but no one has had a greater impact than the Canadian scientist Ray 
Lemieux.
[7] His group was responsible for the first synthesis of sucrose and 
introduction of 
1H and 
13C NMR spectroscopy to the field for structural 
elucidation. Lemieux identified endo- and exo-anomeric and reverse anomeric 
effects and developed key glycosylation reactions such as halide-ion assisted 
catalysis for the preparation of -glycopyranosides. Today, carbohydrate research 
has expanded from only being an obscure area for a small number of dedicated 
scientist, to become a large scientific subject, located at the interface between 
chemistry and biology. The main questions addressed by carbohydrate chemists  12
today differ from those of Emil Fischer´s days, which dealt mainly with 
fundamental properties of the molecules themselves. Instead, carbohydrate 
chemistry has entered a new era, were the biological researchers need of complex 
carbohydrates is the driving force of the synthetic chemistry. Therefore, the 
method development for synthetic carbohydrate chemistry and the understanding 
of the chemical biology of carbohydrates is more important than ever. 
 
1.2 Biological Roles of Carbohydrates 
In the past, carbohydrates were considered to be solely of use for storage and 
supply of energy and as skeletal components. Examples of such components are 
the polysaccharides starch and glycogen as reserve energy substances and 
cellulose and chitin as structural compounds. This view of carbohydrates was 
challenged in 1963 when a protein from seeds of Canavalia ensiformis (jack bean) 
was isolated and demonstrated ability to bind to carbohydrates on erythrocytes
[8]. 
In 1982, the first mammalian carbohydrate binding protein was identified
[9] and 
this sparked interest into the wider roles of carbohydrates in biological systems. 
The importance of glycoconjugates, especially of glycoproteins and glycolipids, 
were discovered and it was found that the carbohydrate part of glycoconjugates 
might act e.g. as antigens and receptors for proteins. The study of carbohydrates 
within biological systems has illustrated that they are involved in a number of 
biological functions such as cell-cell recognition and cell-external agent 
interactions. These interactions can initiate biological events such as fertilization, 
cell growth and cell differentiation, immune responses, inflammation, viral and 
bacterial infections, cancer metastasis, to mention just a few
[10-13](Figure 1).  
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Figure 1. Schematic illustration of cell-cell and cell-external agent carbohydrate 
interactions. Picture taken from the former BioCarb AB catalogue. 
 
Even short carbohydrate sequences can be used for carrying biological information 
and as shown in the human blood groups they may only differ in a simple change 
in oligosaccharide structure. The carbohydrate structure can also modify the 
physiochemical properties of a protein, influence and stabilize its conformation 
and protect the protein against proteolytic digestion. Furthermore, the 
oligosaccharide structure can serve as signals for protein targeting, for example the 
terminal sialic acid residue is vital for the survival of glycoproteins in blood. 
Desialylated glycoproteins are rapidly cleared from circulation by carbohydrate 
specific receptors on hepatocytes and macrophages. The discoveries of the 
important roles of carbohydrates in biological systems have made carbohydrates 
pharmacologically interesting as targets for drugs. Therapeutic agents based on 
carbohydrates or synthetic modifications thereof are used as enzyme inhibitors, 
immune stimulators, carditonic, anti-ulcer, anticoagulant, antiviral and 
antibacterials
[14-20]. Due to the structural complexity of many natural bioactive 
carbohydrates, simplified structures and synthetic analogues are desired to create 
further understanding of their biological role.  
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1.3 Carbohydrate and Glycopeptide Synthesis 
 
1.3.1 Carbohydrate synthesis 
 
Since unprotected carbohydrates often are capable of existing in both pyranose and 
furanose forms, and have a number of hydroxyl groups which are often of similar 
reactivity, its necessary to use protective groups that mask the hydroxyl groups and 
direct the stereochemistry of glycosylation reactions. Further, the glycosidic bond 
can exist in two different anomeric forms, usually depicted as the - and -forms, 
it is necessary to control the stereochemistry as well as the reactivity at the 
anomeric center. The reactivity mainly depends on the configuration of the 
saccharide unit, and to a large degree also on the substitution pattern
[21]. In general, 
acyl groups, such as acetyl and benzoyl groups, reduce the reactivity at the 
anomeric center, while ether groups such as benzyl groups increase it. Formation 
of a glycosidic bond generally involves a donor with a leaving group, an acceptor 
with a free hydroxyl and an activator. Nearly all methods available for the 
formation of the glycosidic linkage utilize a glycosyl donor that is a precursor of 
either an intermediate oxocarbenium ion or at least a species that has significant 
positive charge at the anomeric carbon atom. This high-energy intermediate is 
susceptible to nucleophilic attack from the acceptor present in the reaction 
mixture. If the protective group attached to C-2 position, e.g. an ester group, of the 
glycosyl donor is capable of giving anchimeric assistance (neighbouring group 
participation), the oxocarbenium ion, which is transiently formed, will give rise to 
the more stable 1,2-dioxocarbenium ion (acetoxonium ion) (Scheme 1). The 
dioxocarbenium ion can be steroselective opened in a trans-fashion and generate a 
1,2-trans-glycoside (pathway C), or if the nucleophilic attack occurs at the 
dioxocarbenium ring, the reaction will yield an orthoester
[22] (D). Pathway D is 
reversible, thus orthoesters are easily activated by electrophiles back to the 1,2-
dioxocarbenium ions, which makes them versatile intermediates in carbohydrate 
synthesis.  
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Scheme 1. Possible reaction pathways in the glycosylation reaction of donors possessing a 
participating neighbouring group. 
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This principle of directing the stereoselectivity at the anomeric center towards 1,2-
trans-glycosides has generally been very successful. The 1,2-cis-glycosylation, e.g. 
the formation of an -glycoside in the galacto- and gluco-series, is much more 
difficult (Scheme 1). This requires a non-participating neighbouring group, such as 
an alkyl ether at C-2. The -glycoside is then favoured due to the anomeric effect. 
However, solvent and temperature also influences the stereochemical outcome of 
the reaction, and generally - and -mixtures are formed (pathway A and B) 
[23-25]. 
-Glycosides can also be formed by in situ anomerisation, a soluble catalyst is 
employed to cause rapid equilibration between the - and the less stable -glycosyl 
halide and nucleophilic attack of the acceptor form the -glycoside via an SN2 
mechanism
[26] (Scheme 2). 
 
O
PO
R'O
Br
O
PO
R'O
Br O
PO
R'O
O
PO
R'O
OR
OR
ROH,
slow reaction
ROH,
fast reaction
soluble promotor,
e.g. Br-
Major product,1,2-cis-
glycoside
Minor product, 
1,2-trans-glycoside
P = Protective groups
ROH = Acceptor
R' = Non-participating group
Rapid equilibrium,
via ion-pair
 
 
Scheme 2. The 1,2-cis glycosylation reaction, via the halide-ion assisted in situ 
anomerisation process. 
 
There are a large number of glycosylating agents and donors that have been 
developed, the most common donors are the thioglycosides
[27-29], 
trichloracetamidates
[30, 31], glycosyl halides
[24] and 4-pentenyl glycosides
[32, 33]. In 
this thesis, thioglycosides have mainly been employed as donors, as they are stable 
compounds that are easy to prepare and react selectively at the anomeric center 
with soft activating electrophiles such as DMTST. On the other hand, hydroxyl 
groups of the thioglycosides are hard nucleophiles, which can be selectively 
functionalised using hard electrophiles, without affecting the alkyl- or arylthio 
group. Due to this fact, thioglycosides can be considered as highly versatile 
building blocks for oligosaccharide synthesis. Thioglycosides are also very useful 
in the preparation of the less stable bromo sugars that are useful for example in -
glycosylations, according to the previously mentioned halide-ion assisted 
anomerisation mechanism.  
 Carbohydrates can also be synthesized without using protective group 
manipulations. Enzymes that catalyse regio- and stereoselective couplings between 
saccharides are present in all living organisms. Two main classes of glycosylating 
enzymes exist, the glycosyltransferases using mono- or dinucleotide sugars as 
donors and the glycosidases, which naturally hydrolyse the glycoside bond
[34-36]. 
Glycosyltransferases are highly specific in the formation of glycosides, however 
the availability of many of the necessary transferases is a limiting factor. The 
recent advances in genetic engineering and recombinant techniques have begun to 
remedy this drawback. Instead, the synthetically complex mono- and dinucleotide 
sugars needed as donors are often limiting for large-scale preparative applications. 
The glycosidases have the advantage of wider availability and lower cost, but they  16
are not as specific in synthetic reactions. Another drawback of glycosidases is that 
they are dependent of the thermodynamic equilibrium, as the reaction is reversible 
and therefore generally do not give high yields. In future, enzymatic methods in 
carbohydrate synthesis can be expected to become standard methodology. In paper 
II of this thesis, the substrate scope of a synthetically useful glycosyltransfease has 
been investigated.  
 
1.3.2 Glycopeptide synthesis  
The synthesis of glycopeptides can be realized by different strategies. 
Glycopeptides can be prepared either by direct attachment of the carbohydrate to 
the completed target peptide or by the use of a glycosylated amino acid building 
block in a stepwise peptide assembly. The first approach has often failed in 
solution synthesis of O-glycopeptides, due to low solubility of the peptide acceptor 
in organic solvents. However, peptides can be N-glycosylated
[37] in solution and 
polymer bound peptides can be both N-  and  O-glycosylated
[38-40]. 
Glycosyltransferases can also be used for direct O-glycosylation of peptides
[41], but 
low availability of these enzymes restricts this approach. Synthesis of glycosylated 
amino acids for use as building blocks in a stepwise fashion is the most common 
method both in solution and solid phase glycopeptide synthesis.
[42-48] Solid phase 
synthesis has become attractive due to fast assembly, the possibility of automation 
and reduction of the number of chromatographic purification steps. During the 
synthesis of building blocks suitable for O-glycopeptide synthesis, an activated 
glycosyl donor is coupled to an N- and C-terminally protected hydroxy amino acid. 
The  O-glycosidic bond is sensitive to both strong acid and base. Due to this, 
protective groups of the glycosylated amino acid must be removable using mild 
conditions. The carbohydrate is usually protected with acetyl groups, which can be 
removed after the peptide synthesis under mild conditions, dilute methoxide in 
methanol
[49-51] or hydrazine hydrate in methanol
[52-54]. In solid phase synthesis the 
N-amino group is usually protected with the base labile fluoren-9-
ylmethoxycarbonyl (Fmoc) group, which can be removed by treatment with 
piperidine
[55, 56] or morpholine
[57]. As C-terminal protective groups, tert-butyl
[47, 58], 
allyl
[59-61], benzyl
[62], phenacyl
[63, 64] and pentafluorophenyl
[65] esters have been 
frequently used. All C-protective groups except the pentafluorophenyl ester are 
removed before use in the solid phase synthesis. In paper IV, analogues of the 
analgetically active glycopeptide contulakin-G were synthesized according to the 
previously mentioned stepwise glycosylated Fmoc-amino acid building block 
approach.    17 
 
2. Synthesis of the Non-reducing Di- and 
Trisaccharide End of the NOR-antigen 
2.1 Introduction 
Human sera contain many “natural” anti-carbohydrate antibodies directed against 
structures absent on the cells of the host or present in a cryptic form. 
Polyagglutination of erythrocytes, when antibodies or lectins bind to carbohydrate 
recognition domains (CRD) and form cell precipitates, occur when an unusual 
structure is exposed on cell surface of an individual and is recognized by 
antibodies present in human sera. Well-known examples are the -galactosyl 
antibodies in human sera that recognize the -gal epitope, Gal--(13)-Gal--
(14)-GlcNAc-R, and which are responsible for the acute rejection of 
xenotransplants
[66, 67]. Another carbohydrate epitope terminated with an -linked 
galactose residue is the extremely rare NOR antigen, a neutral glycolipid on the 
surface of erythrocytes responsible for the NOR polyagglutination
[68]. An inherited 
NOR-polyagglutination has so far been identified in two families
[69, 70], when the 
erythrocytes of these people are treated with human serum (blood group AB) 
aggregation occurs. This indicates a common presence of novel anti -galactosyl 
antibodies in human sera. The structure of the NOR1 antigen has recently been 
established as Gal--(14)-GalNAc--(13)-Gal--(14)-Gal--(14)-Glc-
Ceramide
[68]. The non-reducing terminal end contains the unusual structural 
element Gal--(14)-GalNAc- which has hitherto only been demonstrated in 
NOR glycolipids and in amphibium oviductal mucins
[71] and not been synthesized 
before. In order to verify the structures and supplying material for further 
immunological studies, NOR1 di- and trisaccharide structures of the non-reducing 
terminal end was synthesized. 
 
2.2 Synthetic strategy 
Disconnection of the trisaccharide 10 gives three monomeric building blocks; 7
[72], 
3
[73] and 4
[74], previously known in the literature (Scheme 3). Benzyl groups were 
chosen as persistent groups during the synthesis, to be able to form the -
glycosidic bond. The disaccharide building block containing building blocks 3 and 
4 had to be formed first, in order to avoid having two different thioglycosides 
during coupling. The phthalimido group was chosen as nitrogen protecting group 
of the monosaccharide 3 in order to form a -glycosidic bond between 3 and 4. 
The galactose monomer 3 could be formed by inversion of configuration at the C-4 
position of the corresponding easier available gluco-compound by activation and 
subsequent SN2 substitution with a suitable O-nucleophile
[75]. Retrosynthetic 
analysis of the disaccharide 15 gives two building blocks 7 and 12. The 
thioglycoside donor 7  was chosen in order to form a -glycosidic bond. The 
acceptor 12 could be formed from 3 by DMTST coupling using benzyl alcohol as 
acceptor, followed by deacetylation. 
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Scheme 3. Retrosynthetic analysis of NOR di- and trisaccharides. 
 
2.3 Synthesis and evaluation 
2.3.1 Synthesis 
Synthesis of the trisaccharide 10 was carried out using the monosaccharide 
building blocks 7
[72],  3
[73] and 4
[74] (Scheme 4). The N-phthalimido 
monosaccharide 3 was synthesized using a slightly modified literature procedure. 
Treatment of 1
[75] with triflic anhydride gave triflate 2, and subsequent SN2 
substitution of the triflate with cesium acetate in DMF yielded 3, possessing the 
correct galacto-configuration in 4-position. Compound 3 was then coupled with 
acceptor  4, which formed the -(1-3)-glycosidic bond of 5 using DMTST as 
promotor. Deacetylation of the disaccharide 5 using sodium methoxide in 
methanol gave 6 in 37% yield calculated from 4.
[76] Compound 6 was further -
glycosylated using the tetra-benzylated thioglycoside 7 as donor and DMTST as 
activator, which gave 8 in 70% yield. Deprotection of the N-phtalimido moiety of 
8 with hydrazine hydrate and subsequent N-acetylation gave 9 in almost 
quantitative yield. The synthesis of the trisaccharide was completed by catalytic 
hydrogenation of 9, which gave 10 in 61% yield. The overall yield of 10 for the 
synthetic sequence, calculated from 1, was 11%.   19 
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Scheme 4. Synthesis of NOR-trisaccharide 10. 
 
The disaccharide 15 was synthesized from the monosaccharide building blocks 
7
[72] and 12 (Scheme 5). The monosaccharide 12 was prepared by glycosylation of 
the galactosamine derivative 3 using DMTST and benzyl alcohol as acceptor to 
give 11 in 97 % yield. Deacetylation of 11 gave 12 in 95% yield. -Glycosylation 
using DMTST gave the disaccharide 13 in 66% yield. Further, phthalimido 
deprotection and N-acetylation gave 14 in 93% yield. Finally, catalytic 
hydrogenation gave disaccharide 15. The overall yield of 15 over the synthetic 
sequence, calculated from 3, was 40%.   20
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Scheme 5. Synthesis of NOR disaccharide 15. 
 
2.3.2 Biological evaluation 
The ability of the synthesized oligosaccharides 10 and 15 to react with anti-NOR 
antibodies isolated from human sera was investigated by measuring the 
hemagglutination of papain treated NOR erythrocytes. The NOR-antibodies were 
weakly inhibited by galactose, and 8- and 2400 times stronger by the di- and 
trisaccharide, respectively. The reference substance -Gal-(13)-Gal, known as 
the terminal part of the -gal epitope, did not show any inhibition at all. To verify 
the specificity of these reactions, the inhibition of the anti--Gal-(13)-Gal 
antibodies was also investigated. These antibodies were weakly inhibited by 
galactose, slightly more strongly by the -Gal-(13)-Gal disaccharide, while 10 
and 15 were not displaying any inhibition. These results show that the disaccharide 
15 and the trisaccharide 10 binds specifically to the anti-NOR antibodies and that 
the galactose reducing end is important for effective binding. Further biolological 
studies of the NOR di- and trisaccharides have been published.
[77-79]   21 
 
3. Synthesis of Deoxy- and Acylamino 
Derivatives of Lactose for use in Acceptor 
Studies of N. meningitides N-
Acetylglucosaminyltransferase 
3.1 Introduction 
Glycosylation is a common and complex form of posttranslational modification of 
proteins and peptides in biological systems. The carbohydrates range from single 
sugars to elaborate, multibranched structures. Glycosyltransferases
[80] are essential 
components in this post-translational machinery, which transfer monosaccharides 
from high-energy donors, nucleotide sugars, to saccharide acceptors or proteins. 
Chemically, glycosyltransferases can be used as preparative tools in laboratory 
synthesis of biologically active carbohydrates.
[81-86] These enzymes give regio- and 
stereospecific glycosylations without protective group manipulations and reduce 
the number of synthetic steps. The bacterial -(13)-N-
acetylglucosaminyltransferase (lgtA gene from Neisseria meningitidis) was 
recently cloned and expressed in E.coli and acceptor and donor substrates were 
investigated.
[87]  -(13)-N-acetylglucosaminyltransferase use galactosyl 
derivatives as acceptors and UDP-GlcNAc as a donor to catalyse the formation of 
a -GlcNAc-(13)-Gal glycosidic linkage. By examining different substrates for 
the enzyme, it was found that only UDP-GlcNAc and UDP-GalNAc of the 
common nucleotide sugars could be used as donors.
[87] On the acceptor side, the 
enzyme could glycosylate a variety of terminal -and -pyranose derivatives of the 
D-galacto configuration. It was found that p-nitrophenyl--lactoside was the best 
acceptor in these experiments and acceptors with a hydrophobic aglycon were 
more active as substrates. To expand the studies on the acceptor side, deoxy- and 
acylamino derivatives of phenyl -lactoside were synthesized and used as 
acceptors in an enzymatic assay. 
 
3.2 Synthetic Strategy 
Retrosynthetic analysis of the 2´-deoxy derivative 24 gives that the deoxy function 
could be formed by reduction of a thionocarbonate or xanthate starting from a free 
hydroxyl group
[88, 89] (Scheme 6). Selective protection of the 2´-position is readily 
achieved by starting from two monosaccharide building blocks, 18 and 19. The 
donor 19 was selectively protected with an acetyl group in the 2´-position using a 
participating group during coupling to form a -glycosidic bond and also to have a 
protective group that could be easily removed after coupling. The acceptor 18 
could be formed by reductive benzylidene acetal opening, under conditions which 
selectively releases a free hydroxyl in 4´-position.  
 The 3´-deoxy-phenylactoside 31 could be formed using two different 
approaches; using the greater reactivity of the 3´-hydroxyl than the axial 4´-
hydroxyl starting from 28, or using the benzyl protected disaccharide 42. The 
disaccharide 28 could be formed by hydrolysis of an 3´, 4´-isopropylidene acetal.  22
The benzylated disaccharide 42, which is also used in the synthesis of the 3´-
aminoacyl disaccharides 48 and 49, could be synthesized by selective allylation in 
the 3´-position, followed by benzylation of the other hydroxyl groups and finally 
deallylation.  
 Compound  28 can also be used for preparation of the 4´-deoxy analogue 35 by 
the sequential selective 3´-benzylation, 4´-thionocarbonate formation and 
deoxygenation.  
  Analysis of the 6-deoxy derivative 39 suggests that an oxidative ring opening of 
the 4´,6´-benzylidene acetal could be a successful approach. By employing 
bromide as nucleophile in the oxidative ring opening, and choosing benzoyls as 
protective groups, the resulting bromine in 6-position could be removed by 
catalytic hydrogenation.  
  The 3´-acylamino derivatives 48, 49 could be obtained by selective reduction of 
the 3´-oxime followed by acylation. The corresponding ketone is easily prepared 
from 42 by a suitable oxidation protocol. Compound 42, as previously mentioned, 
is prepared by 3´-selective allylation.   23 
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Scheme 6. Retrosynthetic analysis of deoxy- and acylamino derivatives of phenyl--
lactoside 
 
3.3 Synthesis and Evaluation 
3.3.1 Synthesis 
Synthesis of the 2´-deoxy-derivative 24 was carried out starting from the 
monosaccharide building blocks 18
[90] and 19
[91] (Scheme 7). The monosaccharide 
18 was prepared from phenyl 4,6-O-benzylidene--D-glucopyranoside  16
[92] 
starting with benzylation using benzyl bromide/NaH in DMF, followed by 
selective benzylidene acetal opening using NaCNBH3 and HCl, yielding the 2,3,6-
tribenzyl derivative 18 in 37% from 16. DMTST
[93] mediated glycosylation of 18 
with 19 gave the disaccharide 20 in 70% yield. The disaccharide was then treated 
with sodium methoxide in methanol to give a free hydroxyl in 2´-position 21 in 
almost quantitative yield. Formation of the xanthate 22 followed by tributyltin 
hydride reduction gave 23 in 56% yield. It is worth mentioning that it was found  24
necessary to employ the xanthate as reacting group in all cases when the rest of the 
hydroxyls were protected as benzyl ethers. In the cases where benzoyls were 
chosen as protective groups, thionocarbonates worked well in the deoxygenation 
reactions. Finally, catalytic hydrogenation yielded the 2´-deoxy compound 24 in 
94 %. The overall yield of 24 over the synthetic sequence, calculated from 16, was 
13%. 
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Scheme 7. Synthesis of 2´-deoxy Phenyl -lactoside 24. 
 
For the synthesis of the 3´-deoxy compound 31, Phenyl -lactoside  25
[94] was 
converted into the 3´,4´-diol 28 (Scheme 8). Synthesis of 28 started with 3´,4´-
isopropylidene acetal formation, followed by benzoylation, to give 27 in 63% 
yield. Acetal hydrolysis under mild acidic conditions gave 28 in 89% yield. 
Selective 3´-functionalization of the diol 28 with phenylchlorothionoformate and 
further tributyltin-mediated radical deoxygenation gave 30 in only 8% yield. The 
poor yield obtained through this strategy was mainly due to the lack of protection 
on the 4´-position during the tributyltin reduction. Subsequent synthesis of the 
same compound used a different, unpublished, approach. Debenzoylation of 30 
gave the 3´-deoxy target compound 31 in 88% yield. The overall yield of 31 over 
the synthetic sequence, calculated from 25, was only 4%. 
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Scheme 8. Synthesis of 3´-deoxy phenyl -lactoside 31. 
 
The synthesis of the 4´deoxy derivative 35 starts with monobenzoylation of the 3´-
position of the previously used diol 28 (Scheme 9). Employing benzoyl chloride in 
pyridine, gave the 3´-protected compound 32 in 60% yield. Formation of the 4´-
thionoformate, followed by radical mediated deoxygenation gave 34 in 76% yield. 
Debenzoylation of 34 with sodium methoxide in methanol gave the 4´-deoxy 
derivative 35 in 90% yield. The overall yield of 35 over the synthetic sequence, 
calculated from 28, was 41%. 
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Scheme 9. Synthesis of 4´-deoxy phenyl -lactoside 35. 
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The 6´-deoxy derivative 39 was prepared from phenyl -lactoside 25 (Scheme 10). 
Starting with 4´,6´-benzylidene acetal formation, followed by benzoylation, gave 
37 in high yield. NBS mediated, oxidative ring opening of the 4´,6´-benzylidene 
acetal
[95] gave compound 38 in 29% yield. The 6´-bromo derivative 38 was 
dehalogenated by hydrogenation over palladium on carbon (Pd/C) and 
debenzoylated to give the target compound 39 in 40 % yield. The overall yield of 
39 over the synthetic sequence, calculated from 25, was 9%. 
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Scheme 10. Synthesis of 6´-deoxy phenyl -lactoside 39. 
 
For the synthesis of the acylamino derivatives 48 and 49, phenyl -lactoside 25 
was selectively allylated in the 3´-position with allyl bromide and dibutyl tin 
oxide, which gave 40 in 47% yield (Scheme 11). Benzylation using benzyl 
bromide/NaH in DMF, followed by a deallylation sequence, employing 
Wilkinson´s catalyst and DBU for the isomerisation and mild acidic hydrolysis of 
the resulting enol ether in acetic acid and water, gave 42 in 81 % yield. The 3´ 
hydroxyl was oxidized into the corresponding ketone 43 with oxalyl chloride and 
DMSO (Swern oxidation) in 93% yield. No epimerisation of either 2´- or 4´-
positions could be detected at this point. Treatment of 43 with hydroxylamine 
hydrochloride under slightly basic conditions formed oxime 44 in 88% yield. 
Reduction of the oxime with LiAlH4 in THF gave the equatorial amine 45. 
Catalytic heterogeneous reduction methods, like Adams catalyst (PtO2) and 
palladium on carbon (Pd/C) were also investigated, but only resulted in incomplete 
conversions and complex product mixtures. Isolation and purification of the free 
amine 45 proved to be difficult. Instead, direct treatment with an acylating reagent 
gave the more easily handled amides; treatment with Ac2O gave 46 in 38% yield 
(over two steps), whereas treatment with benzoylchloride gave 47 in 61% (over 
two steps). At this stage, no axial amide products could be detected. Catalytic 
hydrogenation gave the 3´NHAc derivative 48 (67%) and 3´NHBz derivative 49   27 
(78%) in good yields. The overall yields of 48 and 49, starting from 25, were 5% 
and 9% respectively. 
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Scheme 11. Synthesis of 3´-acylamino derivatives 48 and 49. 
 
The 3´-deoxy phenyl lactoside 31 was also synthesized by an alternative route 
starting from compound 42 (Scheme 12). The xanthate 50 was formed using NaH, 
then treated with carbon disulfide overnight, followed by alkylation with metyl 
iodide. In presence of the radical intiator AIBN the xanthate 50 reacted readily 
with tributyltin hydride forming the 3´-deoxy compound 51 in 42% yield. Finally, 
the benzyl groups were removed by catalytic hydrogenation forming the 3´-deoxy 
phenyllactoside 31 in almost quantitative yield (V, Supplementary material).  
  28
O
OBn
OBn
HO
OBn
O OPh
OBn
OBn
O
BnO O
OBn
OBn
O
OBn
O OPh
OBn
OBn
O
BnO MeS
S
O
OBn
OBn OBn
O OPh
OBn
OBn
O
BnO O
OH
OH OH
O OPh
OH
OH
O
HO
i ii
iii
Reagents and Conditions: i) NaH, Imidazole, THF, 2 h, then CS2, O.N., followed by MeI, 2 h. ii) AIBN, 
Toluene, 75° C, 8h, 42% over two steps. iii) Pd(C) (10%), H2, EtOH, O.N., 98%.
42 50
51 31
 
 
Scheme 12. Alternative synthesis of 3´-deoxy phenyl -lactoside 31. 
 
3.3.2 Evaluation of Acceptor Activity 
The synthesized deoxy- and acylamino-compounds, 24, 31, 35, 39, 48 and 49 were 
used as acceptors in an enzymatic assay, using N.menigitidis  N-
acetylglucosaminyltransferase and 
3H-labeled UDP-GlcNAc as the donor (Figure 
2). The radioactivity of the formed and purified trisaccharides was measured. The 
3´-deoxy derivative 31, and the acylamino compounds 48 and 49 did not function 
as acceptors, this was expected since they have no free hydroxyl group in 3´-
position. These derivatives will later be studied as inhibitors of the enzyme. The 
deoxy derivatives 24, 35 and 39 were then investigated as acceptors. The deoxy 
derivatives 24 and 35 were less active than the reference compound 25, while the 
6´-deoxy derivative 39 showed an almost threefold increase in activity (Figure 2). 
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Figure 2. Acceptor activity of synthesized lactose derivatives. 
 
The 6´-position is remote from the glycosidic bond formation and the reason for 
higher activity could be a product release effect, as it has one less hydrogen bond 
to break after coupling. To control that the 6´-deoxy-derivative was glycosylated 
in the normal way, a preparative enzymatic reaction was preformed employing 39 
as the acceptor and UDP-GlcNAc as donor (Scheme 13). The resulting 6´-
deoxytrisaccharide  52 was isolated and characterized, and proved to be the 
expected glycosylation product.  30
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Scheme 13. Preparative enzymatic synthesis of 6´-deoxytrisaccharide 52. 
 
In conclusion, three acceptors 24, 35 and 39 and three inhibitors 31, 48 and 49 of 
Neissera meningitides  N-acetylglucosaminyltransferase have been synthesized. 
These analogues of phenyl -lactoside  25 were tested in a radioactivity based 
enzymatic assay. The 6´-deoxy derivative 39 was almost three times more active 
than the phenyl -lactoside 25 (reference compound), and the 2´-deoxy 24 and 4-
deoxy 35 derivatives were less active. As expected, the inhibitors 31, 48 and 49 
were not active. The inhibitory capacity of the synthesized derivatives and the 3-
dimentional details of the enzyme–substrate interaction will be further studied, 
using NMR and X-ray crystallography.   31 
 
4. Synthesis of Biotinylated Ligands for 
Optimization of Binding to the 
Asialoglycoprotein receptor 
4.1 Introduction 
The nature of the terminal sugar residues that cap the carbohydrate chains of 
glycoproteins is a major factor in carbohydrate mediated cell-cell and receptor-
ligand interactions. An example of such a process is the binding and uptake of 
desialylated serum glycoproteins mediated by the asialoglycoprotein receptor 
(ASGPr)
[9] found on and selectively expressed by hepatocytes. This endosomal 
uptake leads to clearance of the proteins from circulation.
[96-98] The ASGPr 
interacts with terminal Gal or GalNAc residues of desialylated serum 
glycoproteins and with synthetic cluster glycoside ligands that mimics these 
ligands.
[99-108] Uptake of glycoproteins by this receptor is both a high-affinity and 
high-capacity process. This feature, combined with its specific location on the liver 
cell, makes it an attractive target system for delivery of drugs and genes to this 
metabolically important cell. In order to direct and deliver foreign DNA in a stable 
way into cells in vivo and to promote efficient expression, delivery vectors are 
required. To date, viral vectors have been used with superior efficacy, however, 
issues concerning the safety of the methods have been raised leading to an interest 
in developing safer alternatives. The Bioplex system for non-viral gene delivery 
takes advantage of the specific and stable interaction between peptide nucleic acids 
(PNA) and DNA for anchoring peptide functions to a plasmid vector.
[109-113] This 
approach provides high flexibility in the composition of the vector and results in 
well-defined and stable carrier-complexes with the potential of becoming efficient 
delivery vectors. To adapt the Bioplex vector for hepatocyte targeting, a synthetic 
high affinity ligand must be synthesized and covalently linked to a PNA.
[114] To 
achieve a specific and high uptake into the target cells and for subsequent gene 
expression, optimisation of the targeting ligand is necessary. Structure-activity 
studies of synthetic galactoside ligands have shown that binding to the ASGPr is 
highly dependent on the number of terminal sugars, the distance and three-
dimensional arrangement of the galactosyl residues.
[103, 115] The affinity to the 
ASGPr increases 100-1000 fold for each sugar from mono- to tri-antennary 
galactosides.
[116, 117] Further increasing of galactosyl residues has only shown a 
modest effect. Gal-containing constructs have shown high affinity for the ASGPr 
when long spacers of >20Å are used
[118]. Targeting of the related macrophage 
receptor on Kupffer cells was observed if the spacers were too short.
[119, 120] To 
gain further insight in the structure-binding relationship and to measure the 
binding of ASGPr ligands to target hepatocyte cells, biotin-labelled di-, tri-, and 
hexa-GalNAc-containing ligands have been synthesized. GalNAc residues was 
used instead of Gal since they display 10-50 fold higher affinity.
[102, 121] The 
ligands also have spacers with more than 20Å distances between the GalNAc 
residue to the branching point for further increase of the binding to the ASGPr. 
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4.2 Synthetic Strategy 
Biotinylated clusters containing GalNAc ligands were designed to study and 
optimize binding and uptake to ASGPr. The reason to synthesize biotinylated 
clusters was to use their ability to bind to fluorescent labelled streptavidin, and be 
able to measure the binding and uptake into HepG2 cells using FACS.  
  The synthetic strategy for the synthesis of biotinylated cluster glycosides was to 
use biotinylated lysine coupled to one or more dioxaoctanoic acid linkers (linker 
1). Further coupling with one ore two lysine branching units, followed by coupling 
with the GalNAc-linker acid (ligand-linker 2) gave the complete biotin labeled 
GalNAc construct (Scheme 14).  
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Scheme 14. Conceptual design and retrosynthetic analysis of ligand-linker system for gene 
delivery. 
 
4.3 Synthesis and Biological Evaluation 
4.3.1 Synthesis 
The central building block in the solid-phase synthesis was the O-acetylated 
GalNAc residue linked through a diethylene glycol spacer ending with a 
carboxylic acid function, compound 59 (Scheme 15). This carboxylic acid was 
synthesised starting from the building block 56 and 54. The linker 54 was prepared 
by anion formation of ethylene glycol 53  and treatment with bromoacetic acid 
obtaining a carboxylate, which was in situ benzylated with benzyl bromide to give 
54 in modest yield (19%). Due to its simple character and cheap starting materials,   33 
this reaction could be performed on large scale and pure product could easily be 
isolated by flash chromatography. Per-acetylation of N-acetylgalactosamine  55 
gave 56 in 95% yield. The oxazoline 57 was prepared by treatment of 56 with 
TMSOTf in DCM followed by direct coupling with the spacer 54 yielding the 
GalNAc-linker compound 58 in 79% yield over two steps. Debenzylation of 58 
gave the free carboxylic acid 59 in good yield. The overall yield of 59, calculated 
from N-acetylgalactosamine 55, was 45%.  
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Scheme 15. Synthesis of GalNAc ligand building block 59. 
 
Solid-phase synthesis of the di-GalNAc construct 64, which should be used as a 
reference compound in the biological studies, was carried out (Scheme 16). 
Starting with deprotection of the Fmoc-group from PAL resin (loading level 0.4-
0.7 mmol g
-1) followed by coupling of di-Fmoc-lysine using PyBOP/DIPEA in 
DMF gave 60, again Fmoc deprotection using 20% piperidine to give a di-amine 
61. Coupling of the GalNAc-linker compound 59 and cleavage from resin using 
95% TFA, 5% H2O gave 63. Deacetylation of the sugar residue gave 64 in 15-
29%.  
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Scheme 16. Synthesis of di-GalNAc –lysine building block 64. 
 
The Biotin-labelled di-GalNAc construct 73 was synthesized starting with 
coupling of a biotinylated di-Fmoc-lysine to Pal resin followed by Fmoc 
deprotection to give 66 (Scheme 17). The amine was coupled with the spacer unit, 
Fmoc-amino-3,6-dioxaoctanoic acid and treated with piperidine to give 68. 
Coupling with di-Fmoc-lysine and removal of the Fmoc protecting groups gave 
70. The di-amine was then coupled with the GalNAc-linker compound 59 and then 
cleavage from resin gave 72. Finally, deacetylation using sodium methoxide in 
methanol gave 73 in 25-46% overall yield. 
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Scheme 17. Synthesis of biotin labeled di-GalNAc construct 73. 
 
The tri-GalNAc building block 79 was prepared by two different routes, either 
using solid-phase synthesis or in solution (Scheme 18). For the preparation of 79 
by solid-phase synthesis, commercial N--Fmoc-N--Mtt-Lysine-Wang resin 74 
was treated with piperidine to give the free -amine 75 and then coupling with di-
Fmoc-Lysine gave 76. Mtt deprotection using 1% TFA, 5% TIPS in DCM 
followed by Fmoc removal gave the tri-amine 77. Coupling with the GalNAc-
linker compound 59 gave the resin-bound compound 78, cleavage from resin gave 
the tri-GalNAc linker compound 79 in 34% yield, calculated from loading of 
lysine on the Wang resin. For the preparation of 79 by solution-phase chemistry, 
commercial di-lysine hydrochloride 80 was treated with TMSCl in the precensce 
of a large excess allyl alcohol to produce the allyl ester 81 in 98% yield. Coupling 
with the GalNAc-linker 59 using DCC/HOBt gave compound 82 (80%) and finally 
deallylation yielded 79 in 69%. As the overall yield of the solution phase route B 
was 54%, compared with 34% for the solid phase synthesis route A, it is clear that 
the tri-GalNAc building block 79 should be prepared by solution phase chemistry.  36
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Scheme 18. Two alternative synthetic routes to tri-GalNAc building block 79, by either 
solid phase synthesis (route A), or solution phase synthesis (route B). 
 
The biotin-labelled tri-GalNAc construct was synthesized using one or five linkers 
to produce 87 and 88 (Scheme 19). Coupling of compound 66 with one linker 
followed by Fmoc removal gave compound 68 and coupling with 5 linkers and 
Fmoc removal gave 84. Coupling of 68 and 84 with the tri-GalNAc building block 
79 followed by cleavage from resin gave 85 and 86 respectively. Deacetylation 
gave  87 in 13-24% yield (from PAL resin) and providing 88 in 3-5% yield, 
calculated from PAL resin loading. The low yield of 88 was partly caused by 
incomplete product separation on gel filtration and only a few relatively pure 
fractions were selected and pooled. The small scale (5-10 μmol) was also a reason 
for the lower yield.   37 
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Scheme 19. Synthesis of biotin-labelled tri-GalNAc constructs 87 and 88 with one 
respective five spacer units.  
 
The biotin-labelled hexa-GalNAc construct 91 was prepared by coupling of the 
hexamine 89 (obtained by custom synthesis from a commercial source) with the 
GalNAc linker 59 using TSDU activation to give 90 in 63% yield (Scheme 20). 
Finally, deacetylation gave the biotinylated hexa-GalNAc construct 91 in 50% 
yield.  
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Scheme 20. Synthesis of biotin-labelled hexa-GalNAc construct 91. 
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4.3.2 Biological Evaluation 
To evaluate the ability of the biotin-labelled GalNAc constructs 73, 87, 88 and 91 
to mediate ASGPr specific binding and uptake into human hepatocytes, 
fluorescent- labelled streptavidin was functionalized with the ligand constructs and 
incubated with ASGPr expressing human HepG2 cells. The uptake was monitored 
by FACS analysis of the cells.
[122] The hexa-GalNAc construct 91 resulted in the 
most efficient uptake, 90%. The di-and tri-GalNAc ligands 73 and 87 showed only 
a moderate uptake, but the lower uptake was probably not only an effect of the 
number of GalNAc units. The tri-GalNAc construct 88 containing five linkers 
showed only slightly lower uptake, 80%, than the hexa-GalNAc 91. 
  In conclusion, the biotin-labelled di-, tri-and hexa-GalNAc constructs 73, 87, 88, 
and 91 have been synthesized and the selective ASGPr uptake into human liver 
cells have been studied. The length of the spacer between the GalNAc ligands 
seems to be important, while increasing the number of GalNAc units above three 
seems only to have a minor contribution to the overall affinity.   39 
 
5. Synthesis of Conus Glycopeptides 
5.1 Introduction 
Cone snails (genus Conus) are marine predators harpooning their prey, injecting 
immobilizing venoms. There are over 500 species of cone snails, mainly fish 
hunting, but also worm and mollusc hunting types, living on or near coral reefs in 
tropical waters. Cone snails have a highly sophisticated venom production 
apparatus and delivery system. An example of the latter is the specialized teeth, 
which in effect serve both as harpoon and disposable needle for venom 
delivery
[123]. Since the cone snails cannot swim and move relatively slowly 
compared to other ambulatory predators, it became necessary to develop effective 
defence and hunting strategies. The fast-acting venoms immobilise their prey, 
which is subsequently engulfed and digested by the snail (Figure 3). 
 
 
Figure 3. A cartoon representing the harpoon strategy of a fish-hunting cone snail. Picture 
reproduced from reference 126. 
 
The venoms of these snails are neuropharmacologically interesting, with a 
composition of 50-200 components per species, mainly small peptides, composed 
of 10-35 amino acids
[124-129]. Each Conus  species has evolved its own large 
molecular repertoire of venom component, different from every other Conus 
species. This means that more than 50 000 different pharmacologically active 
components are present in the venoms of all living cone snail species. Only a small 
part of the conopeptides have been characterized and physiologically studied, but 
have shown diverse functionality mainly targeting voltage or ligand gated ion 
channels or G-protein coupled receptors. Conus peptides that target voltage gated 
ion channels include those that delay the inactivation of sodium channels as well 
as those that specifically block sodium channels, calcium channels and potassium 
channels. Peptides that target ligand gated ion channels include antagonists of N-
methyl-D-aspartate (NMDA) and serotonin receptors (5-HT) as well as 
competitive and non-competitive nicotinic receptor antagonists (nAChR). Peptides 
that act on G-protein coupled receptors include neurotensin (NTR) and vasopressin 
receptor agonists. The peptides ability to discriminate between closely related 
molecular isoforms of members of a particular receptor family, leading to high 
specificity and high potency, together with their small size which make them 
relatively easy to synthesize, have altogether led to that several Conus peptides are 
in various stages of clinical development for treatment of human disorders
[130]. 
Venom peptides need to be sufficiently stable to survive chemical degradation in  40
solution at ambient temperature and enzymatic degradation by processing 
proteases present in the venom itself, as well as those in the tissues of prey species. 
This stability is often achieved naturally through the use of post-translational 
modifications and/or use of disulfide bonds
[131], which fold the peptide into a 
stabilized structure. Typical post-translational modifications include amidation (C-
terminal), sulphation (tyrosine)
[132], bromination (tryptophan)
[133-135], glycosylation 
(threonine or serine)
[135-137],  -carboxylation (glutamate)
[138-140], hydroxylation 
(proline)
[135, 141, 142], pyroglutamation (cyclization of glutamate)
[137, 143], and 
isomerization to D-amino acids
[144, 145]. Glycosylation have hereto only been found 
in three Conus peptides; contulakin G from C. geographus
[137],  A-conotoxin 
SIVA from C. striatus
[136] and tx5a from C. textile
[135, 146-148].  
 
5.2 Synthesis of Contulakin-G analogues 
5.2.1 Introduction 
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Figure 4. Native contulakin-G. 
 
Contulakin-G is the first O-glycosylated Conus peptide for which the complete 
structure of both peptide and glycan has been determined (Figure 4). Contulakin-G 
was found to be a 16 amino acid glycopeptide with the sequence 
ZSEEGGSNAT*KKPYIL where the N-terminal was blocked with a 
pyroglutamate residue and Thr 10 was glycosylated with the disaccharide Gal--
(13)-GalNAc-(1)
[137, 149]. The C-terminal of contulakin-G shows a high 
degree of sequence similarity to the neurotensin family of peptides. Contulakin-G 
is the first member of the neurotensin family of peptides isolated from an 
invertebrate source. It binds to three known neurotensin receptor subtypes, human 
neurotensin type 1 receptor (hNTR1), rat neurotensin type 1 and type 2 and the 
mouse neurotensin receptor type 3. Contulakin-G has shown to be a potent broad 
spectrum analgesic in a number of models of acute pain, and even more potent in 
vivo than the known analgesic neurotensin
[150]. The toxicity of contulakin-G also 
appears to be much lower compared with neurotensin. In recognition of these 
properties contulakin-G has entered pre-clinical trials for short-term management 
of post-operative pain
[130]. The biological in vivo activity of contulakin-G was 
compared with the peptide lacking the glycan and the activity of glycosylated 
contulakin-G was found to be significantly higher
[137]. The glycan part seems to be 
important for activity and there are several possible reasons for this fact. For 
example, increased stability to proteolytic degradation, an enhanced uptake 
through the blood brain barrier via facilitated diffusion transport (the glucose   41 
transporter, GLUT-1), or a conformational change of the peptide and/or a change 
in binding to the receptor could be favourable for activity. In order to study the 
importance of the disaccharide structure of contulakin-G three analogues have 
been synthesized. Native contulakin-G has a -glycosidic bond between the Gal-
GalNAc unit and a -glycosidic bond between the GalNAc residue and threonine, 
the configuration in either of this positions have been altered in order to get 
information of the sterochemical relevance. By changing from the natural (13)-
Gal-GalNAc bond to (14) or (16) the importance of the configurational 
pattern can be studied. The (16) disaccharide was considered as prime synthetic 
target, since the configurational difference is larger between (13) and (16) 
than between (13) and (14). The 3-dimensional solution structure of the 
contulakin-G analogues will be investigated by NMR spectroscopy. The biological 
in vivo activity of these analogues will also be studied.  
 
5.2.2 Synthetic Strategy 
The contulakin-G analogue glycopeptides 110, 111 and 112 could be synthesized 
from their respective glycosylated amino acids in a stepwise fashion, starting with 
the C-terminal amino acid attatched to Wang resin. The -Thr analogue 110 could 
be prepared from the amino acid building block 108, obtained according to the 
literature
[42]. The -Gal-(13)--GalNAc-(1) analogue 111 was prepared from 
the glycosylated amino acid 98, which could be formed by coupling of a 
benzylated disaccharide and a N-Boc and C-t-Bu protected threonine. Use of an 
Fmoc protected threonine was not suitable, since the benzyl groups of the formed 
disaccharide amino acid had to be removed after coupling, using catalytic 
hydrogenation, conditions that Fmoc-protective groups usually do not survive. The 
disaccharide could be formed by halide ion assisted glycosylation of 
monosaccharides. Benzyl groups was used on the Gal monomer in order to form a 
-glycosidic bond and an azide group was used in C-2 position of the GalN-
monosaccharide in order to have a non-participating group during the later 
coupling with threonine. The GalN monosaccharide used in the disaccharide 
coupling could be formed by 4,6-benzylidene protection of the intermediate 99. 
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Scheme 21. Retrosynthetic analysis of Contulakin-G analogues. 
 
The -Gal-(16)-GalNAc analogue 112 could be prepared from the amino acid 
building block 107 (Scheme 22). The amino acid 107 could be obtained by 
coupling of a disaccharide with Fmoc-threonine phenacylester. The disaccharide 
could be prepared by AgOTf promoted coupling of acetobromogalactose and a 6-
hydroxy monosaccharide. The 6-hydroxy monosaccharide building block could be 
formed by 3,4-isopropylidene protection of 99. By choosing this strategy, both 
(13)- and (16)-analogues could be prepared from the common intermediate 
99. 
   43 
O
N3
OH
HO
OH
Sp-tol
3,4-Protection,
glycosidation
4,6-Protection,
glycosidation
O
N3
O
PO
OP
Sp-tol
O
PO
OP
PO
OP
O
OP
PO
OP
PO
O
N3
OP
O
OP
Sp-tol
-Galp-(16)--GalNAcp-
(1) analogue
Common Intermediate 99
O
AcHN
O
AcO
AcO
O
AcO
OAc
AcO
OAc
O
CO2H
Me
NHFmoc O
OAc
AcO
OAc
AcO
O
AcHN
OAc
O
OAc
O CO2H
Me
NHFmoc
107 98
-Galp-(13)--GalNAcp-
(1) analogue  
 
Scheme 22. Synthesis of both (13)- and (16)-analogues from the common intermediate 
99, by either 4,6- or 3,4-protection strategy. 
 
5.2.3 Synthesis 
The glycosylated amino acid 108 was prepared according to the literature
[42]. The 
disaccharide-Fmoc amino acid 98 was obtained starting from the monosaccharides 
7 and 93 (Scheme 23). The fully benzylated galactosyl bromide 92 was obtained in 
situ from the thioglycoside 7
[72] using bromine, followed by halide ion assisted 
coupling with 93
[42] forming the disaccharide 94 in 63 % yield. The disaccharide 
was used in glycosylation of Boc-threonine t-butyl ester
[151] employing DMTST as 
promotor, which gave the glycosylated amino acid 95 in 31% yield. This low yield 
could not be improved, although many attempts were made to tune the reaction 
conditions. Catalytic hydrogenation, followed by acetylation yielded compound 97 
in 64%. Removal of the N-Boc and t-Bu protective groups using 50 % TFA in 
dichloromethane, followed by treatment with Fmoc-O-succinimide gave the Fmoc 
protected amino acid 98 in 77% yield. The overall yield of 98 over the synthetic 
sequence, calculated from 93 was 10 %. 
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Scheme 23. Synthesis of glycosylated amino acid building block 98. 
 
The glycosylated amino acid 107 was prepared starting from the monosaccharide 
building blocks 99 and 101 (Scheme 24). The monosaccharide 99 was treated with 
2,2-dimethoxypropane under anhydrous acidic conditions to form the 3,4-
isopropylidene acetal compound 100  in 39% yield.  Silver triflate promoted 
coupling with acetobromogalactose
[152] 101 gave the -(16)-disaccharide 102 in 
86 % yield. DMTST promoted coupling with Fmoc-threonine phenacylester gave 
the disaccharide amino acid 103  in 56% yield. The isopropylidene acetal was 
hydrolysed using 80% aqueous acetic acid, followed by treatment with acetic 
anhydride in pyridine to form compound 105. Reduction of the azide and 
subsequent N-acetylation by treatment with thioacetic acid yielded compound 106. 
Finally, removal of the phenacyl group gave the Fmoc-amino acid derivative 107 
in 89% yield. The overall yield of 107 over the synthetic sequence, calculated from 
99, was 16%. 
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Scheme 24. Synthesis of glycosylated amino acid building block 107. 
 
The glycopeptides 110, 111, 112 were prepared using the respective glycosylated 
amino acid building blocks. Manual Fmoc solid-phase chemistry was used, 
starting with Leu-Wang resin, each coupling was activated with PyBOP/HOBt 
(5eq) and DIPEA (10 eq) in DMF, the Fmoc group was then removed using 20% 
piperidine in DMF. The coupling/deprotection cycles were repeated using the 
appropriate amino acids until the entire peptide sequence had been assembled. 
During coupling of the glycosylated amino acid only 2 equivalents of activated 
amino acid was used. The completed glycopeptide was removed from resin using 
95% TFA and was treated with sodium methoxide in methanol yielding the 
glycopeptides 110 (9%), 111 (37%) and 112 (56%). The glycopeptide 110 was 
obtained in low yield due to leakage of resin from the vessel; during synthesis of 
the two other peptides agitation of the resin was achieved by nitrogen bubbling 
instead of rotating of the vessel. The asparagine and pyroglutamate amino acids 
required longer reaction times and were routinely double coupled. The formed 
glycopeptides were analyzed with NMR and MALDI and will be further used in 
biological as well as NMR conformational studies.  
 
5.3 Synthesis of Conotoxin tx5a 
5.3.1 Introduction 
The 13-amino acid glycopeptide tx5a (Gla-Cys-Cys-Gla-Asp-Gly-Trp*-Cys-Cys-
Thr*Ala-Ala-Hyp-OH, where Trp* = 6-bromotryptophan and Thr = Gal-GalNAc-
Thr) has recently been isolated from the venom of the mollusk-hunting cone snail, 
Conus textile
[135, 147, 148](Figure 5). Tx5a is a conotoxin (a Conus peptide containing  46
disulfide bonds) which has a conserved arrangement of the cysteine residues (--
CC--CC--) and a consensus signal sequence of its prepropeptide precursor 
common for all members of the T-superfamily conotoxins
[147]. This conotoxin is 
one of the most highly modified gene products known today, containing nine of 13 
post-translationally modified amino acids. The peptide contain four cysteins 
forming two disulfide bonds, two -carboxyglutamate residues, one 6-
bromotryptophan, one hydroxyproline and one glycosylated threonine (Gal-
GalNAc). The role of tx5a is not completely known, but seems to be involved in 
interactions with Ca
2+ channel subtypes that regulate neurotransmitter release from 
presynaptic neurons
[135]. Native tx5a was reported to cause hyperactivity and 
spasticity when injected intracranially into mice
[147].  
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Figure 5. Proposed structure of native Conus toxin tx5a (115). 
 
In order to verify the structure of tx5a, it was recently chemically synthesized. 
However, the synthesized product was found to be different from the native 
peptide
[146]. NMR studies of the native tx5a suggested that the glycan part contain 
a -Gal-(13)-GalNAc glycosidic bond instead of the biologically more common 
-glycosidic bond. The stereochemistry of the 6-bromotryptophan amino acid is 
not known either. To be able to verify the most possible structure of tx5a, a peptide 
containing the -Gal-(13)-GalNAc glycoside and L-6-Br-tryptophan was 
synthesized. 
 
5.3.2 Synthetic Strategy 
The glycopeptide 115  could be prepared from the glycosylated amino acid 
building block 98 previously synthesized in paper IV of this thesis. The disulfides 
of the peptide could be formed selectively by orthogonal protection of the cysteine 
residues using t-BuS and Acm groups (Scheme 25).   47 
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Scheme 25. Synthetic strategy for Conus toxin tx5a. 
 
5.3.3 Synthesis 
The tx5a glycopeptide was synthesized manually by Fmoc-solid-phase chemistry 
using Wang resin (V, Supplementary material). Fmoc-amino acids with 
appropriate side chain protection was used, t-butyl ester protection of -
carboxglutamic acid and aspartic acid, t-butyl ether protection of hydroxy-proline 
and S-t-butyl disulfide protection of Cys
2, 8 and Acm protection of Cys
3,9. O-acetyl 
groups were used to protect the glycosylated threonine 98, whose synthesis is 
described in paper IV of this thesis. The Fmoc-6-bromo-L-tryptophan amino acid 
was obtained from commercially available 6-bromo-D/L-thryptophan by N-
acetylation, followed by enzymatic kinetic resolution using an aminoacylase from 
porcine kidney to yield the L-amino acid, previously known in the literature.
[153] 
Finally, protection using Fmoc-O-Su gave the 6-bromo-L-tryptophan
[154]. The 
amino acids were sequently coupled using HBTU/HOBt/ DIPEA in DMF and the 
Fmoc protecting groups were removed using 20% piperidine in DMF. After the 
last coupling cycle removal from resin using 95% TFA, 2.5 % TIPS and 2.5% H2O 
yielded the acetylated peptide in 6 %. Treatment with methoxide in methanol gave 
the deacetylated product in 52 % yield. Reduction of the S-S-tBu protective groups 
using TCEP gave the free thiols of Cys
2,8 in 22 % yield. Oxidation using 
K3Fe(CN)6 gave the Cys
2,8 disulfide, which was followed by iodine oxidation to 
form the final glycopeptide in 38% yield. The structure of the synthesized 
glycopeptide 115 was confirmed by MALDI mass spectrometry and the material 
will be compared with tx5a by HPLC co-elution and NMR spectroscopy.  48
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